Graeme Martin, PhD
Dr. Martin is President and CEO of Takeda Ventures, Inc, with day-to-day responsibility for operations. Since joining Takeda Ventures in 2003, Dr. Martin has been responsible for building a portfolio of strategic investments representing more than $45 million under management. Previously, Dr. Martin spent more than 35 years in multinational pharmaceutical and biotech R&D. He worked on three novel drug IND candidates, including zolmitriptan, an acute treatment for migraine now marketed worldwide under the brand name Zomig®. He is also the author of more than 85 peer-reviewed publications and book chapters.
Dr. Martin received his Bachelor of Science degree in Pharmacology from the University of Bath, UK and his doctorate from University College, London, UK.